Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
| ▸ | CNR1 | P21554 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5941246 | 0.89 | CASR (0.49) | ALOX12CNR1ALDH1A1MAPTFAAH | |
| SCHEMBL17615841 | 0.88 | ALOX12 (0.54) | ALOX12CNR1ALDH1A1MAPTKDM4C | |
| SCHEMBL455989 | 0.88 | KDM4C (0.55) | ALOX12CNR1ALDH1A1MAPTKDM4C | |
| SCHEMBL469470 | 0.88 | KDM4C (0.55) | ALOX12CNR1ALDH1A1MAPTKDM4C | |
| SCHEMBL14695046 | 0.87 | MAPT (0.43) | ALOX12CNR1ALDH1A1MAPTKDM4C | |
| SCHEMBL14695044 | 0.87 | MAPT (0.43) | ALOX12CNR1ALDH1A1MAPTKDM4C | |
| SCHEMBL1822294 | 0.87 | ALDH1A1 (0.54) | ALOX12CNR1ALDH1A1MAPTKDM4C | |
| SCHEMBL1822295 | 0.87 | ALDH1A1 (0.54) | ALOX12CNR1ALDH1A1MAPTKDM4C | |
| SCHEMBL13251770 | 0.87 | KDM4C (0.51) | ALOX12ALDH1A1MAPTKDM4CEPHX2 | |
| SCHEMBL13540681 | 0.86 | ALOX12 (0.52) | ALOX12CNR1ALDH1A1MAPTKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169905-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200046738-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| EP-2813486-B1 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170246193-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-9708245-B2 | Fatty acid acylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9458094-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9272984-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9139516-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9085527-B2 | Fatty acid acylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150099723-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| EP-2813486-A1 | Fatty acid acetylated salicylates and their uses | Catabasis Pharmaceuticals, Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8846972-B2 | — | — | 2014-09-30 | — | — | US | disclosed |
| US-20140221323-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735378-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735379-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8729293-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| WO-2010006085-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200046738-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | ALOX12 26/4885CNR1 984/4885ALDH1A1 285/4885 |
| US-20150099723-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | ALOX12 26/4885CNR1 984/4885ALDH1A1 285/4885 |
| US-20170246193-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | ALOX12 26/4885CNR1 984/4885ALDH1A1 285/4885 |
| US-20140221323-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | ALOX12 26/4885CNR1 984/4885ALDH1A1 285/4885 |
| US-20210169905-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | ALOX12 26/4885CNR1 984/4885ALDH1A1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.